/
The terms we, us, our, Dar or the Company refer collectively to Dar Bioscience, Inc. and its wholly-owned subsidiaries, unless otherwise stated or the context otherwise requires. Unless otherwise stated, references to particular years, quarters, months or periods refer to our fiscal years ending December 31 and the associated quarters, months and periods of those fiscal years.
$2.37
$0.04 (-1.66%)
Price from 12 days ago
The business is unprofitable at the operating level (-1315.51% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 10429.4% YoY with margins expanding 238376.7pp. However, free cash flow softened 310%, worth monitoring whether this is timing or structural.
Free cash flow declined 310% versus the prior year, cash generation momentum has weakened. Negative free cash flow of -$10M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1M
▲ +10429.4% YoY
Net Income (TTM)
-$12M
▼ -230.6% YoY
Op. Margin
-1034.38%
▲ +238376.7pp YoY
ROIC
-224.22%
▲ +1053.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$10M
▼ -309.6% YoY
Op. Cash Flow (TTM)
-$10M
▼ -280.6% YoY
Net Debt
-$17M
Net Cash Position
Cash & Equiv.
$19M
5Y CAGR: +6.1%
Continue Research